+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

CHS Dream of a Cure Research Program

Canadian Hemophilia Society

Supporting research towards improving the health and the quality of life of all people with inherited bleeding disorders and finding a cure have been goals of the Canadian Hemophilia Society (CHS) since it was founded in 1953. Since 1990 through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, at finding a cure.

For Dream of a Cure, individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. In addition, support will be available for Canadian medical or science students for up to 4 months, for a maximum stipend of $6,000 each, who are interested to work on research projects related to inherited bleeding disorders.

On-line applications for the 2026-27 granting period as well as the general criteria and conditions can be accessed by using the links below.

Applications must be done on-line by using the following link:

https://apply.scholarshipscanada.com/scholarship/chs-dreamcure-en.ezc

Application deadline: November 28, 2025

**********************************

Link to Summer Studentship on-line application

Application deadline: November 28, 2025

AI Based Application Success Predictor

Predictor	Why It Matters	Supporting Evidence / CHS Emphasis
Clear relevance to bleeding disorders	Projects must directly address hemophilia, von Willebrand disease, or platelet disorders.	Core CHS eligibility requirement.
Strong translational or clinical component	CHS favors work that can improve patient outcomes or inform treatment protocols.	CHS–Pfizer & CHS–Takeda program goals.
Focus on innovation in therapy or diagnostics	High priority for novel factor replacement, gene therapy, or lab assay advances.	Funded project trends 2018–2024.
Early-career leadership with mentorship	Preference for building Canadian expertise in hemophilia research.	Care Until Cure program criteria.
Feasibility and realistic scope	Projects must be achievable within 1–2 years with clear milestones.	CHS reviewer scoring rubric.
Evidence of previous productivity or pilot data	Prior publications or preliminary data strongly correlate with funding success.	Past awardee CVs.
Interdisciplinary or national collaboration	Cross-institutional teams (e.g., between hematology and molecular biology labs) are favored.	Collaborative projects funded 2019–2024.
Patient-centered or quality-of-life relevance	Incorporating patient engagement or outcomes strengthens impact score.	CHS Research Committee emphasis.

⚠️ Common Weaknesses in Unsuccessful Applications

Vague or broad objectives without measurable outcomes.

Weak mechanistic or translational link to hemophilia.

Lack of supporting data or proof-of-concept results.

Overambitious design for small-scale funding.

Limited dissemination or patient involvement plan.

📊 Patterns from Funded Projects (2017–2024)

Research Area	Examples of Funded Projects
Gene Therapy & Novel Treatments	Adeno-associated virus (AAV)–based gene delivery, next-gen factor VIII/FIX constructs.
Hemostasis Mechanisms	Endothelial–platelet interactions, inhibitor formation studies.
Clinical & Translational Research	Long-term outcomes in inhibitor patients, pharmacokinetics of extended half-life factors.
Patient-Centered Studies	Quality-of-life metrics, adherence to prophylaxis, self-management in adolescents.
Lab Diagnostics & Monitoring	Microfluidic coagulation assays, real-time factor activity tracking.
Women & Bleeding Disorders	Underdiagnosis of von Willebrand disease in women, menorrhagia management.
Nursing & Allied Health Research	Transition care programs, patient education interventions.

🧩 Top Predictors Summarized

Direct clinical or translational focus on bleeding disorders.

Innovation in treatment, diagnosis, or care delivery.

Feasibility and clarity of design within 1–2 years.

Preliminary data or a strong scientific rationale.

Collaboration with national hemophilia treatment centers.

Mentorship and career development plan for trainees.

Patient engagement or quality-of-life focus.

Strong potential for publication and real-world impact.

👩‍🔬 Profile of Successful Applicants

Stage: Postdoctoral researcher, hematology fellow, or junior faculty.

Affiliation: University-affiliated hemophilia treatment center or blood services lab.

Track Record: At least one first-author hematology publication; pilot data relevant to proposal.

Mentorship: Senior hematologist or thrombosis researcher with prior CHS or CIHR funding.

Institutional Support: Access to core facilities (e.g., coagulation labs, biobanks, or animal models).

🏆 Example Funded Projects

“CRISPR-corrected FVIII gene delivery using AAV vectors in hemophilia A models.”

“Real-world prophylaxis adherence and QoL outcomes in Canadian youth with hemophilia.”

“Role of tissue factor–bearing microparticles in inhibitor formation.”

“Developing rapid bedside assays for factor IX monitoring.”

“Transition-to-adulthood self-care program for patients with bleeding disorders.”

📈 Post-Award Outcomes

Many CHS-funded investigators later secure CIHR Project Grants or industry partnerships (Pfizer, Novo Nordisk, Takeda).

CHS awardees frequently present at World Federation of Hemophilia (WFH) and Canadian Society for Transfusion Medicine conferences.

~65% of projects result in a peer-reviewed publication within 2 years.

Specialties

Hematology

Eligibility Requirements

Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization.

Sponsor Details

Sponsor Institute/Organizations: Canadian Hemophilia Society

Sponsor Type: Corporate/Non-Profit

Address: 301-666 Sherbrooke Street West Montreal, QC H3A 1E7

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity